0000885725-23-000004.txt : 20230201 0000885725-23-000004.hdr.sgml : 20230201 20230201063448 ACCESSION NUMBER: 0000885725-23-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230201 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230201 DATE AS OF CHANGE: 20230201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 23574687 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20230201.htm 8-K bsx-20230201
0000885725false00008857252023-02-012023-02-010000885725us-gaap:CommonStockMember2023-02-012023-02-010000885725bsx:SeniorNotedue2027Member2023-02-012023-02-010000885725bsx:A550MCPSSeriesAMember2023-02-012023-02-01


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
_____________________________________________________________________


Date of Report (Date of earliest event reported): February 1, 2023

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                          (Zip Code)

Registrant's telephone number, including area code:   508 683-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par value per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per shareBSX PR ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐



ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 1, 2023, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits


Exhibit No.        Description

104            Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
            document



SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                
Date:February 1, 2023BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson
Susan Thompson
Vice President, Chief Corporate Counsel, and Assistant Secretary


 EX-99.1 2 q42022earningsrelease.htm EX-99.1 Q4 2022 EARNINGS RELEASE Document

imagea.jpg

FOR IMMEDIATE RELEASE

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR
FOURTH QUARTER AND FULL YEAR 2022

Marlborough, Mass. (February 1, 2023) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for the period, which includes an approximate $0.04 negative impact of the Italian payback, compared to $0.45 a year ago.

For the full year 2022, the company generated net sales of $12.682 billion, growing 6.7 percent on a reported basis, 11.1 percent on an operational1 basis and 8.7 percent on an organic2 basis, including a negative 50 basis point impact associated with the Italian government payback provisions, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $642 million or $0.45 per share, compared to $985 million or $0.69 per share a year ago, and delivered full year adjusted4 EPS of $1.71, including the approximate $0.04 negative impact of the Italian payback, compared to $1.63 a year ago.

“Our global team continues living our mission to transform lives, and I’m proud of the results we achieved in the fourth quarter and throughout 2022,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “In the year ahead we remain committed to our goals of delivering new, meaningful innovations to benefit patients globally while continuing to deliver differentiated financial performance.”

Fourth quarter financial results and recent developments:

•Reported net sales of $3.242 billion, representing an increase of 3.7 percent on a reported basis, compared to the company's guidance range of 2 to 4 percent; 8.7 percent on an operational basis; and 7.1 percent on an organic basis, compared to the company's guidance range of 7 to 9 percent, all compared to the prior year period.

•Reported GAAP net income available to common stockholders of $0.09 per share, compared to the company's guidance range of $0.23 to $0.28 per share, and achieved adjusted EPS of $0.45 per share, compared to the guidance range of $0.45 to $0.48 per share.

•Achieved the following net sales growth in each reportable segment5, compared to the prior year period:
◦MedSurg: 4.4 percent reported, 8.5 percent operational and organic
◦Cardiovascular: 6.4 percent reported, 12.1 percent operational and 9.4 percent organic

•Achieved the following net sales growth/(declines) in each region, compared to the prior year period:
◦U.S.: 10.5 percent reported and operational
◦EMEA (Europe, Middle East and Africa): (0.8) percent reported and 10.8 percent operational
◦APAC (Asia-Pacific): (4.1) percent reported and 9.8 percent operational
◦LACA (Latin America and Canada): 14.6 percent reported and 17.7 percent operational
◦Emerging Markets7: 11.6 percent reported and 23.3 percent operational

•Received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the AGENT™ Drug Coated Balloon (DCB) in Japan to treat patients with in-stent restenosis (ISR) and coronary small vessel disease (SVD), with launch anticipated in the first half of this year.

•Completed enrollment in the CHAMPION-AF clinical trial, a randomized, head-to-head study with 3,000 patients evaluating the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure Device compared to non-vitamin K antagonist oral anticoagulants for stroke prevention in a broad population of patients with non-valvular atrial fibrillation.

•Completed enrollment in the SOLIS randomized clinical trial to assess WaveWriter Spinal Cord Stimulator Systems (SCS) for the treatment of patients with chronic low back and/or leg pain who have not undergone spinal surgery (NSBP, Non-Surgical Back Pain/VB, Virgin Back). The study met its primary endpoint; SCS demonstrated superior outcomes compared with Conventional Medical Management at three-month follow-up.

•Began enrollment in the ACURATE Prime XL Nested Registry, which is designed to assess outcomes from patients receiving the larger ACURATE Prime™ Aortic Valve XL within the ACURATE IDE clinical study in the U.S. Also announced, at PCR London Valves, late-breaking data from the European ACURATE neo2 Post Market Clinical Follow-up study supporting the clinical procedural success and safety of the ACURATE neo2™ Aortic Valve System to treat patients with severe aortic stenosis, including a high procedural success rate and low rates of mortality and paravalvular leak.

•Presented positive data from the ELEGANCE registry during a late-breaking presentation at the 2022 Vascular InterVentional Advances (VIVA) conference, which highlighted that the study is currently exceeding its goal to increase the representation of women and underrepresented minorities in clinical trials for drug-eluting peripheral therapies. Patients enrolled in the registry will be followed for up to five years, allowing for the evaluation of long-term outcomes and the gathering of critical clinical insights into underrepresented patient populations.

•Announced agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) , subject to customary closing conditions, to expand the Boston Scientific endoluminal surgery portfolio and enable a measured entry into the endobariatric market.

•Announced strategic investment to acquire majority stake in Acotec Scientific Holdings Limited, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures, subject to customary closing conditions.


1. Operational net sales growth excludes the impact of foreign currency fluctuations.
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3. Unplanned reserves established in connection with the activation of the Italian government payback provision, aimed at rationalizing public spending and requiring medical device companies to pay back a portion of spend exceeding allocated healthcare budgets.
4. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items.
5. In the first quarter of 2022, we reorganized our operational structure and have aggregated our core businesses, each of which generate revenues from the sale of medical devices, into two reportable segments comprised of MedSurg and Cardiovascular. Within the Cardiovascular segment, the newly formed Cardiology division represents the combined former Rhythm Management and Interventional Cardiology businesses. We have revised prior period amounts to conform to the current year presentation.
6. In 2022, reflects sales reserves established for Italian government payback provisions, not allocated to reportable segments. In 2021, includes net sales associated with Specialty Pharmaceuticals prior to the sale of the business on March 1, 2021. Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our medical device reportable segments.
7. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.






Fourth Quarter Net Sales by Business and Region:
Change
Three Months Ended December 31,Reported BasisLess: Impact of Foreign Currency FluctuationsOperational BasisLess: Impact of Recent Acquisitions / DivestituresOrganic Basis
(in millions)20222021
   Endoscopy$571 $558 2.4 %(5.1)%7.4 %— %7.4 %
   Urology477 441 8.2 %(3.6)%11.8 %— %11.8 %
   Neuromodulation249 244 2.1 %(2.8)%4.9 %— %4.9 %
MedSurg5
1,297 1,243 4.4 %(4.1)%8.5 %— %8.5 %
   Cardiology1,529 1,422 7.5 %(5.6)%13.2 %3.6 %9.6 %
   Peripheral Interventions476 462 3.0 %(5.8)%8.8 %— %8.8 %
Cardiovascular5
2,005 1,884 6.4 %(5.7)%12.1 %2.7 %9.4 %
3,302 3,127 5.6 %(5.0)%10.7 %1.6 %9.0 %
Other6
(60)— (100.0)%— %(100.0)%— %(100.0)%
Net Sales$3,242 $3,127 3.7 %(5.0)%8.7 %1.6 %7.1 %
Change
Three Months Ended December 31,Reported BasisLess: Impact of Foreign Currency FluctuationsOperational
 Basis
(in millions)20222021
U.S.$1,986 $1,798 10.5 %— %10.5 %
EMEA657 662 (0.8)%(11.6)%10.8 %
APAC536 559 (4.1)%(13.9)%9.8 %
LACA122 107 14.6 %(3.1)%17.7 %
3,302 3,127 5.6 %(5.0)%10.7 %
Other6
(60)— (100.0)%— %(100.0)%
Net Sales$3,242 $3,127 3.7 %(5.0)%8.7 %
Emerging Markets7
$445 $398 11.6 %(11.7)%23.3 %

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions / divestitures are not prepared in accordance with U.S. GAAP.

Full Year Net Sales by Business and Region:
Change
Year Ended
December 31,		Reported BasisLess: Impact of Foreign Currency FluctuationsOperational BasisLess: Impact of Recent Acquisitions / DivestituresOrganic Basis
(in millions)20222021
   Endoscopy$2,221 $2,141 3.7 %(4.4)%8.1 %— %8.1 %
   Urology1,773 1,583 12.0 %(2.9)%14.9 %5.3 %9.7 %
   Neuromodulation917 909 0.9 %(2.6)%3.5 %— %3.5 %
MedSurg5
4,911 4,633 6.0 %(3.5)%9.5 %1.8 %7.7 %
   Cardiology5,932 5,422 9.4 %(5.1)%14.5 %4.0 %10.4 %
   Peripheral Interventions1,899 1,820 4.4 %(4.8)%9.1 %— %9.1 %
Cardiovascular5
7,831 7,242 8.1 %(5.0)%13.1 %3.0 %10.1 %
12,742 11,875 7.3 %(4.4)%11.7 %2.5 %9.2 %
Other6
(60)13 (+100)%— %(+100)%— %(+100)%
Net Sales$12,682 $11,888 6.7 %(4.4)%11.1 %2.4 %8.7 %
Change
Year Ended
December 31,		Reported BasisLess: Impact of Foreign Currency FluctuationsOperational
 Basis
(in millions)20222021
U.S.$7,632 $6,901 10.6 %— %10.6 %
EMEA2,526 2,518 0.3 %(12.1)%12.4 %
APAC2,116 2,070 2.2 %(10.2)%12.4 %
LACA469 386 21.6 %(2.2)%23.8 %
12,742 11,875 7.3 %(4.4)%11.7 %
Other6
(60)13 (+100)%— %(+100)%
Net Sales$12,682 $11,888 6.7 %(4.4)%11.1 %
Emerging Markets7
$1,715 $1,429 20.0 %(9.3)%29.3 %

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions / divestitures are not prepared in accordance with U.S. GAAP.
















Guidance for Full Year and First Quarter 2023

The company estimates net sales growth for the full year 2023, versus the prior year period, to be in a range of approximately 5 to 7 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.11 to $1.21 and estimates adjusted EPS, excluding certain charges (credits) of $1.86 to $1.93.

The company estimates net sales growth for the first quarter of 2023, versus the prior year period, to be in a range of approximately 3 to 5 percent on a reported basis, and approximately 6 to 8 percent on an organic basis. First quarter organic guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.23 to $0.26 and adjusted EPS, excluding certain charges (credits) of $0.42 to $0.44.


Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may", "intend," and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2023; our financial performance; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on our operations and financial results; the impact of foreign currency fluctuations; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
CONTACT:
Media:Kate HaranisInvestors:Lauren Tengler
508-683-6585 (office)508-683-4479 (office)
Media RelationsInvestor Relations
Boston Scientific CorporationBoston Scientific Corporation
kate.haranis@bsci.comBSXInvestorRelations@bsci.com




BOSTON SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended
December 31,		Year Ended
December 31,
in millions, except per share data2022202120222021
Net sales$3,242 $3,127 $12,682 $11,888 
Cost of products sold1,011 971 3,956 3,711 
Gross profit2,231 2,155 8,727 8,177 
Operating expenses:
Selling, general and administrative expenses1,163 1,153 4,520 4,359 
Research and development expenses330 320 1,323 1,204 
Royalty expense13 11 47 49 
Amortization expense199 192 803 741 
Intangible asset impairment charges— 197 132 370 
Contingent consideration net expense (benefit)(33)(18)35 (136)
Restructuring net charges (credits)6 23 24 40 
Litigation-related net charges (credits)131 128 173 430 
Loss (gain) on disposal of businesses and assets22 (30)22 (78)
1,830 1,975 7,078 6,978 
Operating income (loss)402 180 1,649 1,199 
Other income (expense):
Interest expense(64)(87)(470)(341)
Other, net58 26 (38)218 
Income (loss) before income taxes396 120 1,141 1,076 
Income tax expense (benefit)256 26 443 36 
Net income (loss)$140 $94 $698 $1,041 
Preferred stock dividends(14)(14)(55)(55)
Net income (loss) available to common stockholders$126 $80 $642 $985 
Net income (loss) per common share - basic$0.09 $0.06 $0.45 $0.69 
Net income (loss) per common share - assuming dilution$0.09 $0.06 $0.45 $0.69 
Weighted-average shares outstanding
Basic1,432.7 1,425.2 1,430.5 1,422.3 
Assuming dilution1,442.4 1,436.2 1,439.7 1,433.8 




BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
Three Months Ended December 31, 2022
in millions, except per share data Gross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(1)
Reported$2,231 $1,830 $402 $(6)$396 $140 $(14)$126 $0.09 
Non-GAAP adjustments: 
Amortization expense— (199)199 — 199 175 — 175 0.12 
Acquisition / divestitures-related net charges (credits)24 (29)53 (44)9 59 — 59 0.04 
Restructuring and restructuring-related net charges (credits)16 (12)28 — 28 25 — 25 0.02 
Litigation-related net charges (credits)— (131)131 — 131 101 — 101 0.07 
Investment portfolio net losses (gains)— — — (38)(38)(32)— (32)(0.02)
EU MDR implementation costs13 (6)19 — 19 17 — 17 0.01 
Deferred tax expenses (benefits)— — — — — 42 — 42 0.03 
Discrete tax items— — — — — 129 — 129 0.09 
Adjusted$2,285 $1,452 $833 $(88)$745 $656 $(14)$642 $0.45 
Three Months Ended December 31, 2021
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(1)
Reported$2,155 $1,975 $180 $(60)$120 $94 $(14)$80 $0.06 
Non-GAAP adjustments:
Amortization expense— (192)192 — 192 180 — 180 0.13 
Intangible asset impairment charges— (197)197 — 197 171 — 171 0.12 
Acquisition / divestiture-related net charges (credits)32 (19)50 (57)(7)(4)— (4)(0.00)
Restructuring and restructuring-related net charges (credits)20 (39)58 — 58 51 — 51 0.04 
Litigation-related net charges (credits)— (128)128 — 128 98 — 98 0.07 
Investment portfolio net losses (gains)— — — 2 2 2 — 2 0.00 
EU MDR implementation costs9 (5)14 — 14 13 — 13 0.01 
Deferred tax expenses (benefits)— — — — — 46 — 46 0.03 
Discrete tax items— — — — — 16 — 16 0.01 
Adjusted$2,216 $1,396 $819 $(115)$704 $667 $(14)$653 $0.45 
(1) For the three months ended December 31, 2022 and 2021 the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders.
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.


















BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
Year Ended December 31, 2022
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(2)
Reported$8,727 $7,078 $1,649 $(508)$1,141 $698 $(55)$642 $0.45 
Non-GAAP adjustments:
Amortization expense— (803)803 — 803 694 — 694 0.48 
Intangible asset impairment charges— (132)132 — 132 102 — 102 0.07 
Acquisition / divestitures-related net charges (credits)97 (206)303 (18)285 338 — 338 0.24 
Restructuring and restructuring-related net charges (credits)65 (45)110 — 110 96 — 96 0.07 
Litigation-related net charges (credits)— (173)173 — 173 133 — 133 0.09 
Investment portfolio net losses (gains)— — — (30)(30)(28)— (28)(0.02)
EU MDR implementation costs46 (25)71 — 71 62 — 62 0.04 
Debt extinguishment charges— — — 194 194 149 — 149 0.10 
Deferred tax expenses (benefits)— — — — — 140 — 140 0.10 
Discrete tax items— — — — — 129 — 129 0.09 
Adjusted$8,935 $5,694 $3,241 $(362)$2,880 $2,514 $(55)$2,459 $1.71 
Year Ended December 31, 2021
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Available to Common Stockholders
Impact per Share(2)
Reported$8,177 $6,978 $1,199 $(123)$1,076 $1,041 $(55)$985 $0.69 
Non-GAAP adjustments:
Amortization expense— (741)741 — 741 676 — 676 0.47 
Intangible asset impairment charges— (370)370 — 370 318 — 318 0.22 
Acquisition / divestiture-related net charges (credits)65 34 31 (482)(450)(453)— (453)(0.32)
Restructuring and restructuring-related net charges (credits)79 (112)191 — 191 169 — 169 0.12 
Litigation-related net charges (credits)— (430)430 — 430 331 — 331 0.23 
Investment portfolio net losses (gains)— — — 181 181 137 — 137 0.10 
EU MDR implementation costs32 (17)49 — 49 45 — 45 0.03 
Deferred tax expenses (benefits)— — — — — 132 — 132 0.09 
Discrete tax items— — — — — (5)— (5)(0.00)
Adjusted$8,353 $5,343 $3,010 $(423)$2,587 $2,391 $(55)$2,336 $1.63 
(2) For the year ended December 31, 2022 and 2021, the effect of assuming the conversion of Mandatory Convertible Preferred Stock (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income available to common stockholders.
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.











BOSTON SCIENTIFIC CORPORATION
Q1 and FY 2023 GUIDANCE RECONCILIATIONS
(Unaudited)

Net Sales
Q1 2023 EstimateFull Year 2023 Estimate
(Low)(High)(Low)(High)
Reported growth3 %5 %5 %7 %
Less: Impact of foreign currency fluctuations(4)%(4)%(1)%(1)%
Operational growth7 %9 %6 %8 %
Less: Impact of certain acquisitions / divestitures1 %1 %— %— %
Organic growth6 %8 %6 %8 %

Earnings per Share
Q1 2023 EstimateFull Year 2023 Estimate
(Low)(High)(Low)(High)
GAAP results$0.23 $0.26 $1.11 $1.21 
Amortization expense0.12 0.12 0.47 0.47 
Acquisition / divestiture-related net charges (credits)0.03 0.02 0.12 0.10 
Other adjustments0.04 0.04 0.16 0.15 
Adjusted results$0.42 $0.44 $1.86 $1.93 





Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share we exclude certain charges (credits), which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or any Quarterly Report on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) available to common stockholders and GAAP net income (loss) per common share - assuming dilution, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded


from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) available to common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

EX-101.SCH 3 bsx-20230201.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bsx-20230201_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bsx-20230201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Class of Stock [Domain] Class of Stock [Domain] City Area Code City Area Code Entities [Table] Entities [Table] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Entity Information [Line Items] Entity Information [Line Items] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Common Stock [Member] Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Local Phone Number Local Phone Number Written Communications Written Communications Cover page. Cover [Abstract] Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 bsx-20230201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 imagea.jpg begin 644 imagea.jpg MB5!.1PT*&@H -24A$4@ ! H "6" 8 !73VH' 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

[9T'?%1%U\8#V+%BU_?UT]?>&Z H3004%2PHJ"@*2 ^]]]Y[[QVD]PY) MZ"4)O??>>X?0GN\\L_R&F9_)O?\;?G?FB(1[^NC;NS5\7#N6OAY0)-D;=Z;]3N-043YJ_%P6.G MK:,JRIV'"@6*HBB*HBB*HMP6G+UP"0O7[$#8LBV8OVH["M0?A*"/RB H4WD$ M?2J6OBP*-1YB?IL9L0FCPE:AY9 0Y*K4 T&?54#0&\40]%Y)W).U"CXLT@8= M1\W%Y2LZRD"Y\U"A0%$415$415&4VY(ZO:<:<2 HX,4IQ0<.K<1?,@7KUVS?HF^;EZ M";A\2CXO6E\$@.MBQ^5_)_@/)0X7HZY@W['3.'GV@O6-HBB*HBB*HB0O-7I, MCB,4U.L[S?HU+FNW'T#Z8NUDGV#7/A0,/BJ-JMTFXMIU;=@K=PXI1BA8L&8' M*G4OPY)?54:3Y<.L;15$4 M15$414E>$BH4D.E+-^+!G#5<(@'WDWT8PV#UUOW6%HIR^W/3A0*.'&@Q)$0> MOIH(>K>$ZT'.&(R@#TK)0UD>W]?HBQ6;D^[)'UL*+"DH#_YKP(PW@)EONS[Y M]Z*?@/V3K0V3P+YK0*&SDJDGQ(['M@?ENZH7@*,J1!HH @6]5!@Y*_:POE$4 M15$415&4Y"4Q0@$[*DW, N[WN>SWN>PG_VX\<*:UQ:W'M6O7 SIB6[G]N.E" M0=OA80C*6,XE#O !=K=,%1#T<1G\+W]CC)F[VMHCX9S;"2S,"TQ_%9C]H=A' M;B9_4S (R0!L[2H/42(',)RY#OQ,D8#" (4")Y/?O$*5(4/[FI0L&VO4?QOP)-8QY>;_9Q63/\I^V(.8BZG' O>WU#U\B! M."*!F\U\US7*8$U-X/P>:\<$,#P*2.TD#GC:<>"-4\"T.WPJ@@H%BJ(HBJ(H M2J!)K%!0I_>TV$+!1V60HT)WZ]=;BXV[#N/%GYM@\L+UUC>*$C\W52@8&;(2 MJ;-4=HT<:C[ MD#,^J!^7 MP2N_-,'(T/B[_8\N $(S ;/>9]P/0I^# =O@"1P[=0[7$SF*^.R% M2]AY\+@1,$Z=O6!]Z^+RE:MF=+,GNP^=,*LT/)"]JO&;'OVZ%I:L37@P0ZX ML?_H:3GWI!DH8 F^SXJGVWD MV;\3%BY1H4!1%$51%$4)-$Y" 84 )^C&@S%X1J2CL^S$ MQMV'4;;=&'Q4K!U>+M@,+^9OC _^;HWR'<=A[LIM&!FV$JV'AN**.. D;,56 MM!H2@N .8_#N7ZV-P&&F>6>J@ =RUD#C 3,Q;/'GQG@J;SV\(.?_K%0G5.LV"0O7[+"VC,TR3H1@A_[99L64?*LJUO/]7&SS^;1T\F*L&'LM3!V__ MT1*E6X_$)KE^Y>9QZPH%MEE+*&8)[H+EF^-V^R=5*#!&L> -*V[!5.O ;B2+ M4&";'(.!$0_=YFJ!"@6*HBB*HBA*H(DE%%BQ!FJ+ WSUZC5>YAR,)>"V6SY0J M2V7CA#_W0P,\DZ\^GA;'_Y&O:F-6Q":SK\WQT^=1O]]T/):SALF'3"4[HGKW MR6@NUU"KUU1D"^YJ\O"A+ZH9(>'PB1BA@:, RK8?*PY_33R;KP'2R?G,J SZ M:_3Y/BR-WI.7F&W[3%J"=%_5,K\Q70_)/D'I@UUYS\[@#TKAG<*ML'[G(;.] M*X]MJO;%Y3]S>\.6; M]QK'.^BM?\21KH]ALYQ%B/#UN_&4./L?%VGKZ"AOD.]R5NR!H%?^1JY*/7 Q MRC5_>?>ADUBW\R"V[CV&JMTFN483T$^2SP=SUT3_J>'8MN^H.29M[8Z#L:82 M<+K"=]7[&+^*H[9;#PV+,Y+BPJ7+Z"/.?EISK260NU)/.>8QZU=@[Y%36+O] M@*3AJ!%9'OU:\I;^7J8*2/59!3/:HLF@6;@G:Q7\4*NO$5^)IFK@2.VT,HL"U#,![(7@7-ALQ&U&57@3JV*/F$ AKC M%LQ\&UA=%;AXT)PB^84"FASKE5/ Y-LT;H$*!8JB*(JB*$J@B3VB0$R<53-\ MOOLD8QS&_VN#P7CGSU:X.TME//E=7104Y[3%T!#,6+K1KVD"W<8N=/6:BX/- MJ08<4N^-D&5;<#][^S\LC8=RU<#4Q1NL7UQP&D'^.@.,7S-VWAKKV[@P]L$+ M/S8RPL,YAVD1[4?.C1$*Q-]Z]*M:6+3:>;H N1!U&3_QO!^6,FG[I]5(ZQ=G M:O::@J"/)5_?+X4\U7H[QBZ@\_]TOGIR?EMC-<*-C.?#?O/-%,]/"G: M8KBY=G.O*'!('H4MWVK]JMQ(;B^A@&8I5L6EO4$!CW (NH;CT M=^!TI.M:.3G]B38[WR$F@PT7@=M,+5"A0%$51%$51 DTLH8 ^A_@* M% $\.7+RK)F__V/M_L91#GJK&.[.6@592G?&P&D1B++B 'BR9ML!_/>'AJYS MB-/,'GE?L/<_>[FN9@H"IT^G+][!!/.SV7OX)%[[K3G2YJJ)\ V[K&^=X50 MQB(X<2;N$FVMAH7&$@H>^:J6SU4/F@ZL!<+LXJ#GXQ"@;$/74$.%WX)[!EO"07BU#LZ M_,E@1<\!QVZCN 4J%"B*HBB*HBB!QDDH\+7J 8>Y-Q\:@GL9.-TXP6611ISM M,FW'X.*EV%UWU\79I=-K>N'IV(J3W7SP;.M7[]3I/541,S M0;GQW)Y" 8W'S%@"7W[5#U,_.XLY&1R<_>2P-\0R7D?NV6>0YOQ5!)V*Z^0G MBQT'\IP!5MXF<0M4*% 415$415$"34*% IN2;4990^!=^_#?E;J,Q[5K,3WA M6_<>P6-F#KXXPN*4WR,.KF=P0"<&3 UW[4.AX*/2>+=PF^B@@.'KQ;D6IYLC M#M[^HY59.>#T>6?'FKWRC!G@U#N?$*&@W8@YKFMD_DA>?5JBHQEAX8LSYRZY M AO:>90Q.(Y($DLH,-M(WO?QG?<4"DRL!S>AH%;/*=:ORHWD]A4*C)7%1QDZ MHU6ZU1CQSE',R02$.#G[2; PKHCPX75\VF,+[MV\%0\?O8Q4 10+7I-C3[P- MYB&H4* HBJ(HBJ($FL0*!8P!P!4"C*_"?<7)39.E4JS Z;TG+C8.LG%HQ2GG M=('(C7NL7[TS,G2E:W@]G>'/*IA_3UVRWORVZ] )O%FHI>NX/7@>J0,H M%C!N04?&+7">VG-+H$*!HBB*HBB*$F@2*Q20BIW'F_GWT;Z%.-,_UQV(2U84 M?BY_&.THBT/[L#CC7)$@/L;/7XN[LE6)<>0S!J.U./;DZK7K*-1XB&MJ L]I M3:GFW'X&2Z03_?[?;1#+=P:Y$4-#T_I6H%Q2)>JDBT.6Y M+9B9.'#N(Y_0LT6"C[NM05!B\,1%!*!!Q>M1;J=QW'W:B<.'"15R\:)G\.\I:YDE1%$51DDI2A()Q\]>X?!4Z MK-P_0S#>*M32+"-(3.##:*&@G%D*X8H:!!T'+4"UJ&VD'A:/?T M>DS,]XO7+R$M_]H:>H"TPCB+E 4VS9>\3:RX6_0L&^ M(Z?PGQ\;N7PR2RCXMKI_0D&^FNY"03FD^Z:.&:%@<[.$@A-G+V#JX@WH.G:! MB8E0MOT85.PR :V&AF%F^"837T&)GSM2**#5#8I O321&/#&7LS^]"K"THOC MGXC1!5Z% EIH)%*%1)BX!4\#*+3(5(3F$@I"E&Y'&6E;& ME"-_[<,R>/RKFEBY<;=UI(11NZ>\<,29<3PVYW>]5Q)UND^TME848,J\54B= M6>HYNS<@L<87OGGI5\"+W]='KK*=T;CW%*R2LGSY\JTG&E HR/A/>U>#AW4V M&P3R/)=L-LS:0E$41;E3.''F/$(B-Z.&M+/H@']=N:>)!U!)'+QNXO!%;-R# M\Q<3_JY+BE P:>$ZUWO7]E7$*7_]]^;8;HD!Y3J.BXGZ+]L]E+LF5ENC#7PQ M9HZT"[)6=G.&RQE!P!>,)1"^83<&3H_ 3[7[N_9GVN08J;-4QHC0%=:6+OP5 M"DZ22?N2OUQ)GSOF,47+EZ#7FJ](K93_+AM=^:Q]KO1@L%NPZ? M0..!L_ !8RZ(C\#C<-G'-PJUQ-N%6^%9:3OQ'C'=\U9MM_92O'''"@4NL2#2 M" 9=G]^*Z9]>Q)Q$3$7P*138-CL<#R]:B\=VG< ]% L"&+>@Q#G@T#4K@U,P MR2$4A$5LPKUV)1/'I$4__UX2GM3EVK?OEO!R;*G4Y-CUY"6G*#;3 M%JS!/=FKN.H[IW*3$&/Y93F3EVW0!Z7-"SK=5S51L'9?S(V\M4:RJ%"@*(JB M<$W]CJ/G(WW1MM*F^KDQ[F;@O\\K(4>Y;N@T:CX. M'C]M[2W[G[^(5O^&(<3!"29)$0J,KV*_HV@?QW:B1X>M,QU2EYE"^YBA!M?<,3!EQ6Z(RB#Y"U'(GQ< MQHQ\N'HMQA&YD4(!?8OWIIZUM^+$'2T4T!BWH$Y0.-JD6XN)&<\@[).$347P2RB@A43@ MWCG+\%Q"Y)+*+B?+PY6)$[WWY=1$2[8!"=/^5XC MUHEZ?:::40..QV6%)B^1^KU4*%!BH%!PGS0"S O;O;RP[F/YC<_8F.!+V'U? MVZP&@!$,Y*7'$0:7;Y$I"2H4*(JBW-EP*<"\-?J8:/Y!F%MV+[%" MP:ES%TQ/=/1J 'P7RW&:#YEM;0$5^GR5H%8^>MMG[U3I>Q M"TQ[T;SWY'J^*-\-YRZXIL3VFK0$[XK#>^S4.?.W+PHU&N)ZA\JY.XR<:WWK MPE^A@/2;LA2IN!W;'.F#\6'1MM@O#K8OCIX\AT]*='1=NQ$]RJ/;N(76KRYN ME%#05<[[ 'V"=TO@I?R-37P'7TQ%1B+=FIUX^.AEI Y@W((WY-D>F[@I^#>$FRX4A((TF2OBWJR5<'>6BE[M'K%4\O(URR2]4\(5 5E>XJ;> M]!0/,DA]*G5JSTE&A0%$4Y+XMT_6F*\O"OC@[WM MWW"X.]^'\K[@U6,GQ=_?G09.]^:0(D%8H^(M>92IBDP;L%-%PIHXM#_5K<_+E].V/ +%0J4 MA!)'*&"=)R^H"JV&8^J\59@\=Z5/&S,K$MU'ST.3_C-1J<-H?%ZL+5*SK%'% M_]2C_//OC,%HU"?EET$5"A1%4>Y,.'2^4*.AQN%_(7\CK-@2$RD_/DZ>N8"_ MZ6C3.:>3RO>>M 634RA8N'H[GLE7W^6G\-TD3NB3>6HCU"D8H#C9'W%U @;D M_: T,I?NC"@?;4N.0OB_GQN[WN&R#Y=8/.\6.'#2@G4FO=]4ZX/+5WP[L(T' MSI1CE,+CW]1!Y*8]UK+,<-G^+DX!EK2FSE0>O2B0H&24.(* M!5)F/RN/X=,2/J*%G#I]#F%+-Z!HDR%FCIUI*+F70WG)/_M='2Q?'_\\R9N) M"@6*HBAW)E,6K<<]6<3)E/J_N1<'WQ<,[)+ MF>"/GJL4L&>=4R%,.UG:'9Q:X.G,AZW8AG(=QN+L!=6\S=^6V.$)!H_XS MK5]C4[/'%&GSR'V2^YI*[A5C1OAB\/0(5][;[;'TP694Q(%COJ=9W*FH4.!@ M]8(BS>B"-NG68>*GIS&'<0N\!#E,M%! L^(6/+YI/QXX>3VP<0M. ^M2T$H@ M*4(HD,HGE518O<;ZCC+KB0H%2D+Q)A3T'[_ VB)Q7+]V#2-G1N")KVJZ>B;< MRZ(T0,JT&&ZV2:FH4* HBG+GP=@#>:N+D_E.<3S^;5VL\G"4_675UGVNWFJ* M &Y" 8/6<;4"#N@^=@$> MR57#S*7/4+R#XPH)C,>0*HN\$V4;=@8TZC\C3F#!;?N/(F\-R<.W_L%;?[3$ MYCV'K5]BV'7P!%[]M;GK6MCN$)_KK4(M,6S6M>X^:WVPXO>"WAH/-2 8ZZ14[CS=Y3JY*FX.._HB0 ME498:3)PELOIYSVB@R[O^^]K]C._<1O74H57S"@ _GMDZ$HY_V17>BG4NS MW];&;FE,I%14*% 41;GSX#2#!W**LRQMJ:S!77'6"N*7&.IP)2HZH?)^M86" M;?N.F=$&KQ1LAK?_;&F6,WSUUV:QC-_Q-]H;O[? ?WYLB">_JVNF!'Q4M*T) ML-ATP,P$38D@:[^ MK8L*'<:9@(U.3%F\'H_EJ8U?Z@U$MK)=D#9G=4EG*SG.8)1M-P8_B*/-7OI4 MTK[-4ZF'3Z%EVM(->.NWYBY_BP$CN;SW^Z5P[Q?5<$_6*LA7O;=#.JYCZ*SE M^%3>SZD^KV#$F-R5>Z*P7-?757KBN1\:R+DK($.1=F:IQJM78SHD+EV^C,)- MA^&EGYL8 8/Y_'*!IK&,^4_!XB5Q\K^KUL=,)>&(!OZ;^[TNZ77:Y^4"S?!I MB8Y8+7E,V@Z?X[KW5MN!JV1P:H$O&!^BZ]B%>%_RD\(6)%DHH(5&(G5(!!X*WXC'#IQ'J@ & M.7SL)-#D A!UD^,6W!"A0+[_WT\-D2Y7=>]E3+:Y-UMES(O8:!TU?E0H4!)* MH(6"JU>OXN=:?5VJNGM9S%@.@R:A0H"B*;R M?(EEM3C))I: O#MLH>#2Y2O8M/NP&?:^=OM!;-AYR/SM;OR.O]'6[8C9AG/5 M#QX_DZ3@=KR>R(U[T$XH/1)6N$S%YX3JX^:NB9YRX,3ADV=$Z,QWAMX9#S$B 7QL,1K5N$S%A M_EJ33TXP#RE>K+;S?]ES5*-%SVF7WB#X@C3F93[?">@0H$?QK@% M=5*%H^M_MV#ZIQ! M8N> (S?QV;@A0H&\-'ZLUA/!S8>*@R;;T GQW,9:][5X AP3%0J4A!)HH8#T MG; 0J5F7\MBF+(K),U"\Z5!KBY2'"@6*HBAW'F;9/LY9%^.?/5C'3+M\O:49@*,F+"@5^6CTQ M$[?@B?48G^$TPABW(#F% ML8MV NXQ8

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�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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Document
Feb. 01, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 01, 2023
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 1-11083
Entity Tax Identification Number 04-2695240
Entity Address, Address Line One 300 Boston Scientific Way
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752-1234
City Area Code 508
Local Phone Number 683-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000885725
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BSX
Security Exchange Name NYSE
Senior Note due 2027 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.625% Senior Notes due 2027
Trading Symbol BSX27
Security Exchange Name NYSE
5.50% MCPS, Series A [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share
Trading Symbol BSX PR A
Security Exchange Name NYSE

XML 9 bsx-20230201_htm.xml IDEA: XBRL DOCUMENT 0000885725 2023-02-01 2023-02-01 0000885725 us-gaap:CommonStockMember 2023-02-01 2023-02-01 0000885725 bsx:SeniorNotedue2027Member 2023-02-01 2023-02-01 0000885725 bsx:A550MCPSSeriesAMember 2023-02-01 2023-02-01 0000885725 false 8-K 2023-02-01 BOSTON SCIENTIFIC CORPORATION DE 1-11083 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 false false false false Common Stock, $0.01 par value per share BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share BSX PR A NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 4 22 1 false 3 0 false 0 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports bsx-20230201.htm bsx-20230201.xsd bsx-20230201_def.xml bsx-20230201_lab.xml bsx-20230201_pre.xml q42022earningsrelease.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bsx-20230201.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bsx-20230201_def.xml" ] }, "inline": { "local": [ "bsx-20230201.htm" ] }, "labelLink": { "local": [ "bsx-20230201_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20230201_pre.xml" ] }, "schema": { "local": [ "bsx-20230201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 2, "memberStandard": 1, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20230201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20230201.htm", "contextRef": "icaa2862ac9754af0a5317be9d4fea4fd_D20230201-20230201", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Document", "menuCat": "Cover", "order": "1", "role": "http://www.bostonscientific.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20230201.htm", "contextRef": "icaa2862ac9754af0a5317be9d4fea4fd_D20230201-20230201", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "bsx_A550MCPSSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% MCPS, Series A", "label": "5.50% MCPS, Series A [Member]", "terseLabel": "5.50% MCPS, Series A [Member]" } } }, "localname": "A550MCPSSeriesAMember", "nsuri": "http://www.bostonscientific.com/20230201", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "bsx_SeniorNotedue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "terseLabel": "Senior Note due 2027 [Member]" } } }, "localname": "SeniorNotedue2027Member", "nsuri": "http://www.bostonscientific.com/20230201", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000885725-23-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-23-000004-xbrl.zip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